Neuroendocrine Tumors Clinical Trials Update 2026: Phase-Wise Pipeline Status, Drug Profiles, and Key Developers | Camurus, Orano Med, Vyriad, Pfizer, Takeda Oncology, Hutchison MediPharma, Provectus

(Albany, New York) - November 12, 2026: As per DelveInsight's assessment, globally, Neuroendocrine Tumors pipeline constitutes 115+ key companies continuously working towards developing 130+ Neuroendocrine Tumors treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Neuroendocrine Tumors Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Neuroendocrine Tumors Pipeline Insight, 2026 [https://www.delveinsight.com/sample-request/neuroendocrine-tumors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Neuroendocrine Tumors Market.

Some of the key takeaways from the Neuroendocrine Tumors Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Neuroendocrine Tumors treatment therapies with a considerable amount of success over the years.

*
Neuroendocrine Tumors companies working in the treatment market are Camurus, Orano Med, Vyriad, Inc., Immunomic Therapeutics, Crinetics Pharmaceuticals, Biotheus, Panavance Therapeutics, Nano Pharmaceuticals, Oxford BioTherapeutics, Seneca Therapeutics, Amgen, POINT Biopharma, RayzeBio, and others, are developing therapies for the Neuroendocrine Tumors treatment

*
Emerging Neuroendocrine Tumors therapies in the different phases of clinical trials are- CAM2029, AlphaMedix, Voyager-V1, ITI 3000, Paltusotine, PM8002, GP-2250, BG-P-TAT, OBT-620, SVV-001, Tarlatamab, PNT2003, RYZ101, and others are expected to have a significant impact on the Neuroendocrine Tumors market in the coming years.

*
In September 2026, the FDA granted final approval to Lantheus' BRAVNETSA, a bioequivalent and therapeutically equivalent radiopharmaceutical to LUTATHERA for adults with SSTR-positive GEP-NETs. This approval expands access to lutetium Lu 177 dotatate treatment options.

*
In September 2026, the US FDA approved Curium's BEXLUTRY for adults with somatostatin receptor-positive (SSTR-positive) GEP-NETs, including foregut, midgut, and hindgut tumors. It is a radioligand therapy designed to deliver targeted radiation to tumor cells expressing somatostatin receptors.

*
In August 2026, The FDA has issued tentative approval for Omcazio, a new capsule formulation of cabozantinib, for multiple oncology indications. The therapy is indicated for adults with advanced renal cell carcinoma (RCC) as both a monotherapy and in combination with nivolumab (Opdivo) as first-line treatment. It is also approved for adults with hepatocellular carcinoma (HCC) who have previously received sorafenib (Nexavar), as well as for adults and pediatric patients aged 12 years and older with previously treated, unresectable, locally advanced, or metastatic well-differentiated extrapancreatic neuroendocrine tumors (epNETs).

*
In February 2025, ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech firm, reported encouraging topline findings from its Phase III COMPETE trial. The study evaluated ITM-11 (n.c.a. 177Lu-edotreotide), a targeted radiopharmaceutical therapy, in patients with inoperable, progressive Grade 1 or 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The therapy demonstrated a notable and statistically significant enhancement in progression-free survival (PFS) compared to everolimus, the existing standard treatment option.

*
In January 2025, ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech firm, has reported positive topline results from its Phase 3 COMPETE trial in patients with inoperable, progressive Grade 1 or 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The study showed that ITM-11 (n.c.a. 177Lu-edotreotide), a proprietary targeted radiotherapy, met its primary goal by significantly improving progression-free survival (PFS) compared to everolimus, a standard targeted therapy. Additionally, ITM-11 demonstrated a favorable safety profile and was well tolerated by patients.

*
In January 2025, Exelixis, Inc. (Nasdaq: EXEL) reported results from a subgroup analysis of the Phase 3 CABINET study, focusing on patients with extra-pancreatic neuroendocrine tumors (epNET) originating in the gastrointestinal (GI) tract. The findings showed that cabozantinib improved progression-free survival (PFS) compared to placebo in patients with advanced GI neuroendocrine tumors-a subset of the broader epNET group. These results are set to be presented during Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract at 11:30 a.m. PT on January 24 at the ASCO GI 2025 Symposium.

Neuroendocrine Tumors Overview

Neuroendocrine tumors (NETs) are a diverse group of tumors that originate from neuroendocrine cells. These cells are found throughout the body, particularly in organs such as the gastrointestinal tract, pancreas, lungs, and adrenal glands. Neuroendocrine cells have characteristics of both nerve cells and hormone-producing cells, hence the name.

Get a Free Sample PDF Report to know more about Neuroendocrine Tumors Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/neuroendocrine-tumors-pipeline-insight [https://www.delveinsight.com/report-store/neuroendocrine-tumors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Neuroendocrine Tumors Drugs Under Different Phases of Clinical Development Include:

*
CAM2029: Camurus

*
AlphaMedix: Orano Med

*
Voyager-V1: Vyriad, Inc.

*
ITI 3000: Immunomic Therapeutics

*
Paltusotine: Crinetics Pharmaceuticals

*
PM8002: Biotheus

*
GP-2250: Panavance Therapeutics

*
BG-P-TAT: Nano Pharmaceuticals

*
OBT-620: Oxford BioTherapeutics

*
SVV-001: Seneca Therapeutics

*
Tarlatamab: Amgen

*
PNT2003: POINT Biopharma

*
RYZ101: RayzeBio

Neuroendocrine Tumors Route of Administration

Neuroendocrine Tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Oral

*
Parenteral

*
Intravenous

*
Subcutaneous

*
Topical.

Neuroendocrine Tumors Molecule Type

Neuroendocrine Tumors Products have been categorized under various Molecule types, such as

*
Monoclonal Antibody

*
Peptides

*
Polymer

*
Small molecule

*
Gene therapy

Neuroendocrine Tumors Pipeline Therapeutics Assessment

*
Neuroendocrine Tumors Assessment by Product Type

*
Neuroendocrine Tumors By Stage and Product Type

*
Neuroendocrine Tumors Assessment by Route of Administration

*
Neuroendocrine Tumors By Stage and Route of Administration

*
Neuroendocrine Tumors Assessment by Molecule Type

*
Neuroendocrine Tumors by Stage and Molecule Type

DelveInsight's Neuroendocrine Tumors Report covers around 130+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Neuroendocrine Tumors product details are provided in the report. Download the Neuroendocrine Tumors pipeline report to learn more about the emerging Neuroendocrine Tumors therapies [https://www.delveinsight.com/sample-request/neuroendocrine-tumors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Neuroendocrine Tumors Therapeutics Market include:

Key companies developing therapies for Neuroendocrine Tumors are - Pfizer, Takeda Oncology, Hutchison MediPharma, Provectus Biopharmaceuticals, NanoValent Pharmaceuticals, Camurus, ITM Solucin, Radiomedix, Inc., Orano Med LLC, Clarity Pharmaceuticals, TaiRx, Jiangsu Hengrui Medicine, MedImmune, Genentech, Merck & Co, Peloton Therapeutics, RayzeBio, Ascentage Pharma, Debiopharm, Boehringer Ingelheim, Roche, Ipsen, Medelis Inc., Exelixis, EpicentRx, Inc., Tarveda Therapeutics, Teclison Ltd., Novatek Pharmaceuticals, Phanes Therapeutics, Fujifilm Pharmaceuticals, Jazz Pharmaceuticals, 23andMe, Inc., Celgene, Crinetics Pharmaceuticals Inc., POINT Biopharma, and others.

Neuroendocrine Tumors Pipeline Analysis:

The Neuroendocrine Tumors pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Neuroendocrine Tumors with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Neuroendocrine Tumors Treatment.

*
Neuroendocrine Tumors key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Neuroendocrine Tumors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Neuroendocrine Tumors market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Neuroendocrine Tumors drugs and therapies [https://www.delveinsight.com/sample-request/neuroendocrine-tumors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Neuroendocrine Tumors Pipeline Market Drivers

*
Rising prevalence of the disease, growing Research and Development Activities are some of the important factors that are fueling the Neuroendocrine Tumors Market.

Neuroendocrine Tumors Pipeline Market Barriers

*
However, limited Awareness and Under diagnosis, heterogeneity and Complexity and other factors are creating obstacles in the Neuroendocrine Tumors Market growth.

Scope of Neuroendocrine Tumors Pipeline Drug Insight

*
Coverage: Global

*
Key Neuroendocrine Tumors Companies: Camurus, Orano Med, Vyriad, Inc., Immunomic Therapeutics, Crinetics Pharmaceuticals, Biotheus, Panavance Therapeutics, Nano Pharmaceuticals, Oxford BioTherapeutics, Seneca Therapeutics, Amgen, POINT Biopharma, RayzeBio, and others

*
Key Neuroendocrine Tumors Therapies: CAM2029, AlphaMedix, Voyager-V1, ITI 3000, Paltusotine, PM8002, GP-2250, BG-P-TAT, OBT-620, SVV-001, Tarlatamab, PNT2003, RYZ101, and others

*
Neuroendocrine Tumors Therapeutic Assessment: Neuroendocrine Tumors current marketed and Neuroendocrine Tumors emerging therapies

*
Neuroendocrine Tumors Market Dynamics: Neuroendocrine Tumors market drivers and Neuroendocrine Tumors market barriers

Request for Sample PDF Report for Neuroendocrine Tumors Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/neuroendocrine-tumors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Neuroendocrine Tumors Report Introduction

2. Neuroendocrine Tumors Executive Summary

3. Neuroendocrine Tumors Overview

4. Neuroendocrine Tumors- Analytical Perspective In-depth Commercial Assessment

5. Neuroendocrine Tumors Pipeline Therapeutics

6. Neuroendocrine Tumors Late Stage Products (Phase II/III)

7. Neuroendocrine Tumors Mid Stage Products (Phase II)

8. Neuroendocrine Tumors Early Stage Products (Phase I)

9. Neuroendocrine Tumors Preclinical Stage Products

10. Neuroendocrine Tumors Therapeutics Assessment

11. Neuroendocrine Tumors Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Neuroendocrine Tumors Key Companies

14. Neuroendocrine Tumors Key Products

15. Neuroendocrine Tumors Unmet Needs

16 . Neuroendocrine Tumors Market Drivers and Barriers

17. Neuroendocrine Tumors Future Perspectives and Conclusion

18. Neuroendocrine Tumors Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=neuroendocrine-tumors-clinical-trials-update-2026-phasewise-pipeline-status-drug-profiles-and-key-developers-camurus-orano-med-vyriad-pfizer-takeda-oncology-hutchison-medipharma-provectus]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.